Search

To evaluate the feasibility of serum sCD30 for prediction of acute graft rejection, we analyzed clinical data of 231 patients, whose serum levels of sCD30 were detected by ELISA before and after transplantation. They were divided into three groups: acute rejection group (AR, n = 49), uncomplicated course group (UC, n = 171) and delayed graft function group (DGF, n = 11). Preoperative sCD30 levels of three groups were 183±74, 177±82 and 168±53 U/ml, respectively (P=0.82). Significant decrease of sCD30 was detected in three groups on day 5 and 10 post-transplantation respectively (52 ±30 and 9±5 U/ml respectively, P< 0.001). Compared with Group UC and DGF, patients of Group AR had higher sCD30 values on day 5 post-transplantation (92±27 U/ml vs. 41±20 U/ml and 48± 18 U/ml, P<<0.001). However, sCD30 levels on day 10 post-transplantation were virtually similar in patients of three groups (P=0.43). Receiver operating characteristic (ROC) curve demonstrated that sCD30 level on day 5 post-transplantation could differentiate patients who subsequently suffered acute allograft rejection from others (area under ROC curve 0.95). According to ROC curve, 65 U/ml may be the optimal operational cut-off level to predict impending graft rejection (specificity 91.8%, sensitivity 87.1%). Measurement of soluble CD30 on day 5 post-transplantation might offer a noninvasive means to recognize patients at risk of impending acute graft rejection during early post-transplantation period. [ABSTRACT FROM AUTHOR]